Corgenix Medical Corporation (OTC Bulletin Board: CONX), a worldwide developer and marketer of diagnostic test kits, has announced the availability of its new automation friendly anti-phospholipid assay format.
The new format offers high-volume testing labs the same performance as the currently available Corgenix rapid assay with improved efficiency and high-volume analysis.
"Offering both extended and short assay formats allows us to maintain our leadership position in anti-phospholipid antibody detection," said Douglass Simpson, Corgenix CEO and President. "Our customers can now compete more effectively with enhanced automated performance."
Automated microplate ELISA processing from Corgenix is available for a wide range of anti-phospholipid antibody screening tests, including anti-Cardiolipin (aCL) antibodies, anti-Phosphatidylserine (aPS) antibodies and anti-Beta2 Glycoprotein I IgG antibodies.
As the first company to obtain FDA clearance of its anti-Cardiolipin test, Corgenix maintains its commitment to offer the highest quality tests associated with SLE (lupus) and antiphospholipid syndrome, autoimmune mediated thrombotic diseases. It is estimated that over 3 million individuals in the United States and 10 million worldwide have lupus or lupus-like disorders.
Leveraging the power of automation to boost research